

HAND DELIVERED NOVEMBER 12, 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman et al.

Application Number: 08/972,301

Group Art Unit: 1646

Filed: November 18, 1997

Examiner: D. Basham

Title: Endothelial-Monocyte Activating
Polypeptide III

Attny. Docket No.: PF206D1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AJ listed on the attached form PTO 1449.

Copies of references AA-AC were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 08/483,534, filed June 7, 1995, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 08/483,534 for copies of references AA-AC.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to:

(a) SEQ ID NO:1407 in copending U.S. Patent Application Serial No. 08/401,881; and

(b) SEQ ID NO:6286 in copending U.S. Patent Application Serial No. 08/104,507.

Pursuant to 37 C.F.R. § 1.97, because this Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, a fee of \$240.00 is believed to be due. However, if the Patent and Trademark Office determines otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The Assistant Commissioner is authorized to charge our Deposit Account No. 08-3425 for any fee which may be required in connection with this submission.

Respectfully submitted,

Date: November 12, 1998



Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 309-8504 (phone)

KKH/ur